Pulse Biosciences announced on September 2, 2025, the completion of the first successful procedures in its multicenter IRB-approved PRECISE Benign Thyroid Nodule (BTN) Study. This study utilizes Pulse Biosciences’ nsPFA Percutaneous Electrode System for the treatment of benign thyroid nodules.
The initiation of this study marks a significant step in expanding the body of clinical evidence supporting the treatment of benign thyroid nodules with the company's nPulse technology. The study aims to further assess the safety and effectiveness of the system in a broader clinical setting.
This operational milestone is crucial for the company as it moves into the second half of 2025, focusing on advancing the commercialization of soft tissue ablation in the thyroid market. The data generated from this study will be instrumental in supporting future regulatory submissions and market adoption.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.